What Companies Are In The VanEck Semiconductor ETF?
There’s a lot to love about the VanEck Semiconductor ETF,…
Sell
13
RARE Quote, Financials, Valuation and Earnings
Last price:
$41.49
Seasonality move
:
3.93%
Day range:
$41.10 - $41.95
52-week range:
$37.02 - $60.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.90x
P/B ratio:
11.05x
Volume:
1.5M
Avg. volume:
750K
1-year change:
-13.45%
Market cap:
$3.8B
Revenue:
$434.2M
EPS (TTM):
-$6.47
Analysts' Opinion
-
Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $92.95, Ultragenyx Pharmaceutical has an estimated upside of 123.98% from its current price of $41.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $48.00 representing 100% downside risk from its current price of $41.50.
Fair Value
-
According to the consensus of 14 analysts, Ultragenyx Pharmaceutical has 123.98% upside to fair value with a price target of $92.95 per share.
RARE vs. S&P 500
-
Over the past 5 trading days, Ultragenyx Pharmaceutical has underperformed the S&P 500 by -4.84% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ultragenyx Pharmaceutical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ultragenyx Pharmaceutical has grown year-over-year revenues for 10 quarters straight. In the most recent quarter Ultragenyx Pharmaceutical reported revenues of $139.5M.
Earnings Growth
-
Ultragenyx Pharmaceutical has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Ultragenyx Pharmaceutical reported earnings per share of -$1.40.
Enterprise value:
3.2B
EV / Invested capital:
--
Price / LTM sales:
6.90x
EV / EBIT:
--
EV / Revenue:
6.16x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-7.32x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$450.9M
Return On Assets:
-38.86%
Net Income Margin (TTM):
-106.93%
Return On Equity:
-226.56%
Return On Invested Capital:
-226.56%
Operating Margin:
-94.62%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $343.4M | $410.2M | $522.7M | $98.1M | $139.5M | |
| Gross Profit | $316.9M | $371.7M | $450.9M | $87.1M | $118.5M | |
| Operating Income | -$605.9M | -$592.8M | -$535.7M | -$145.1M | -$132M | |
| EBITDA | -$623.1M | -$547.6M | -$461.5M | -$134.1M | -$108.7M | |
| Diluted EPS | -$9.74 | -$8.97 | -$6.47 | -$2.23 | -$1.40 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $872M | $846.9M | $1B | $599.2M | $799.6M | |
| Total Assets | $1.3B | $1.5B | $1.6B | $1.2B | $1.5B | |
| Current Liabilities | $201.2M | $135.9M | $227.4M | $254M | $285M | |
| Total Liabilities | $602.2M | $551.1M | $1.1B | $1.2B | $1.2B | |
| Total Equity | $666.2M | $933.7M | $468.8M | $31.7M | $353.8M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$344.5M | -$481.2M | -$418.6M | -$117.9M | -$67M | |
| Cash From Investing | -$51M | $103.4M | -$227.5M | $64.3M | -$275.5M | |
| Cash From Financing | $585.1M | $59.4M | $726.7M | $25.2M | $11.2M | |
| Free Cash Flow | -$479.7M | -$553.4M | -$439.5M | -$121.6M | -$68.6M | |
RARE
Sector
Market Cap
$3.8B
$49.2M
Price % of 52-Week High
68.74%
48.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-13.45%
-30.94%
Beta (5-Year)
0.576
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$42.73
200-day SMA
Sell
Level
$47.61
Bollinger Bands (100)
Sell
Level
46.62 - 56.6
Chaikin Money Flow
Buy
Level
22.1M
20-day SMA
Sell
Level
$44.98
Relative Strength Index (RSI14)
Sell
Level
29.19
ADX Line
Sell
Level
27.2
Williams %R
Neutral
Level
-79.4908
50-day SMA
Sell
Level
$47.54
MACD (12, 26)
Sell
Level
-1.75
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
23.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.7837)
Sell
CA Score
(Annual)
Level (-3.3103)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (3.9178)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Stock Forecast FAQ
In the current month, RARE has received 13 Buy ratings 1 Hold ratings, and 0 Sell ratings. The RARE average analyst price target in the past 3 months is $92.95.
-
Where Will Ultragenyx Pharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ultragenyx Pharmaceutical share price will rise to $92.95 per share over the next 12 months.
-
What Do Analysts Say About Ultragenyx Pharmaceutical?
Analysts are divided on their view about Ultragenyx Pharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ultragenyx Pharmaceutical is a Sell and believe this share price will drop from its current level to $48.00.
-
What Is Ultragenyx Pharmaceutical's Price Target?
The price target for Ultragenyx Pharmaceutical over the next 1-year time period is forecast to be $92.95 according to 14 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is RARE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ultragenyx Pharmaceutical is a Buy. 13 of 14 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RARE?
You can purchase shares of Ultragenyx Pharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ultragenyx Pharmaceutical shares.
-
What Is The Ultragenyx Pharmaceutical Share Price Today?
Ultragenyx Pharmaceutical was last trading at $41.49 per share. This represents the most recent stock quote for Ultragenyx Pharmaceutical. Yesterday, Ultragenyx Pharmaceutical closed at $41.50 per share.
-
How To Buy Ultragenyx Pharmaceutical Stock Online?
In order to purchase Ultragenyx Pharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Can Palantir Stock Go?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors…
Will This ETF Beat the Market Over the Next 12 Months?
2024 was another banner year for the US stock market,…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
